Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PLRX | PRESS-RELEASE | bearish | 6/10 | Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue bio | May 11, 2026 |
| CHRS | PRESS-RELEASE | mixed | 6/10 | Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14 | May 11, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s | May 11, 2026 |
| SANA | 8-K | neutral | 4/10 | Sana Biotechnology reported Q1 2026 results with a GAAP net loss of $0.17 per share, narrower than the $0.21 loss in Q1 | May 11, 2026 |
| LENZ | 8-K | mixed | 5/10 | LENZ Therapeutics reported Q1 2026 results with $1.7M in VIZZ product sales (up 19% QoQ) and total revenue of $1.9M, but | May 11, 2026 |
| PLRX | 8-K | neutral | 4/10 | Pliant Therapeutics reported Q1 2026 results with a net loss of $20.0M ($0.32/share), narrower than the $56.2M loss in Q | May 11, 2026 |
| AVTX | CLUSTER | bearish | 6/10 | Four Avalo Therapeutics insiders, including the CFO, CLO, and CMO, sold a total of $1.53M in open-market stock within da | May 11, 2026 |
| OCSAW | 6-K | neutral | 5/10 | Oculis reported Q1 2026 results with a net loss of CHF 28.9 million ($36.8M), improved from CHF 33.2 million ($36.9M) in | May 11, 2026 |
| AKTS | 8-K | neutral | 4/10 | Aktis Oncology reported Q1 2026 financial results, highlighting a net loss of $18.3 million (vs. $15.0 million a year ag | May 11, 2026 |
| ATYR | 8-K | mixed | 6/10 | aTyr Pharma announced it will proceed with a new Phase 3 trial (C-006) for efzofitimod in pulmonary sarcoidosis followin | May 11, 2026 |
| INBX | 8-K | bullish | 8/10 | Inhibrx reported positive interim Phase 2 data for INBRX-106 in first-line HNSCC, showing a 44.0% confirmed objective re | May 11, 2026 |
| MBX | 144 | bearish | 5/10 | Richard B. Bartram, a former officer of MBX Biosciences, filed a Form 144 on May 11, 2026, indicating intent to sell 22, | May 11, 2026 |
| ALLR | 3 | neutral | 1/10 | Jesper Hoeiland filed a Form 3 initial statement of beneficial ownership with Allarity Therapeutics, disclosing zero sha | May 11, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's granted 1,192,234 stock options (816,119 Indian stock options + 376,115 ADR stock options) to eligible emplo | May 11, 2026 |
| COLL | 144 | neutral | 2/10 | Director Garen G. Bohlin filed a Form 144 notice of intent to sell 8,700 shares of Collegium Pharmaceutical common stock | May 11, 2026 |
| GLAXF | 6-K | neutral | 2/10 | GSK filed a 6-K reporting a routine PDMR transaction: Maya Martinez-Davis, President US, acquired 9.455 American Deposit | May 11, 2026 |
| KZR | 25-NSE | neutral | 2/10 | Nasdaq filed a 25-NSE notification to remove Kezar Life Sciences' common stock from listing, effective immediately. This | May 11, 2026 |
| CYTK | PRESS-RELEASE | neutral | 4/10 | Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obs | May 11, 2026 |
| KZR | 8-K | neutral | 8/10 | Kezar Life Sciences has been acquired by Aurinia Pharma U.S., Inc. in a completed tender offer and merger. Shareholders | May 11, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovascular hospitalization | May 11, 2026 |
| AUPH | 8-K | neutral | 5/10 | Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merger. Shareholders rec | May 11, 2026 |
| AGEN | 8-K | bullish | 7/10 | Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY) and net income of $39.2M vs a net loss of $26.4M in | May 11, 2026 |
| ADIL | 8-K | neutral | 3/10 | Adial Pharmaceuticals reported Q1 2026 results with net loss improving to $2.0M from $2.2M YoY, driven by lower R&D spen | May 11, 2026 |
| ALVOW | 6-K | neutral | 4/10 | Alvotech disclosed that the FDA completed a routine cGMP surveillance inspection at its Reykjavik facility, concluding w | May 11, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome | May 11, 2026 |
| FATE | PRESS-RELEASE | bullish | 7/10 | Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell pr | May 11, 2026 |
| MEHA | 8-K | mixed | 7/10 | Functional Brands Inc. (MEHA) announced a binding LOI to acquire BullionFX's Alchemy blockchain assets for $142.9 millio | May 11, 2026 |
| CLRB | PRESS-RELEASE | neutral | 1/10 | Cellectar Biosciences, Inc. announced it will report its Q1 results on May 14, 2026. | May 11, 2026 |
| HRTX | PRESS-RELEASE | bearish | 6/10 | Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v | May 11, 2026 |
| HRTX | 8-K | bearish | 6/10 | Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, driven by a 26.3% drop | May 11, 2026 |